Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Chubb
Accenture
Teva
Cipla
Cantor Fitzgerald
Chinese Patent Office
Merck

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,173,847

« Back to Dashboard

Summary for Patent: 9,173,847
Title:Tablet comprising a fibrate
Abstract: Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.
Inventor(s): Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee: VELOXIS PHARMACEUTICALS A/S (Horsholm, DK)
Application Number:11/449,918
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Formulation;

Drugs Protected by US Patent 9,173,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,173,847

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2005 00527Apr 13, 2005

Non-Orange Book US Patents Family Members for Patent 9,173,847

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,481,078 Solid dosage form comprising a fibrate ➤ Sign Up
7,658,944 Solid dosage form comprising a fibrate ➤ Sign Up
8,124,125 Solid dosage form comprising a fibrate ➤ Sign Up
7,772,273 Stabilized atorvastatin ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Argus Health
Farmers Insurance
Accenture
UBS
Teva
Chubb
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.